
AI is about to change healthcare. These 43 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own Almonty today, you need to believe that Sangdong’s ramp-up and the long-term tungsten offtake with Plansee can eventually turn rapid forecast revenue growth into sustainable profits, despite the company’s history of sizeable losses and dilution. The new US$246.79 million shelf registration, including the ESOP component, fits that story by giving management ample flexibility to fund Sangdong Phase I optimization, potential Phase II growth and the adjacent molybdenum project, while tying staff incentives to equity. In the short term, though, this filing may sharpen two key catalysts for the stock: progress on production and any concrete financing moves under the shelf. It also accentuates existing risks around further dilution and execution at a time when the share price has already been volatile.
However, one of the biggest financing risks here is easy to underestimate at first glance. Almonty Industries' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.Explore 2 other fair value estimates on Almonty Industries - why the stock might be worth over 3x more than the current price!
Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com